A TWO-YEAR DOUBLE-MASKED, RANDOMIZED, SHAM-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ULTEVURSEN IN SUBJECTS WITH RETINITIS PIGMENTOSA (RP) DUE TO MUTATIONS IN EXON 13 OF THE USH2A GENE

Registry ID

SB-421A-006

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

LABORATOIRES THÉA

Start date

2025-10-15

Last update

2024-10-16

Conditions

• RETINITIS PIGMENTOSA (RP)

Related clinical trials

• A PHASE 3, MULTI-CENTER, RANDOMIZED STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF SUBRETINAL OCU400 GENE THERAPY FOR THE TREATMENT OF RETINITIS
• PHASE 3 FOLLOW-UP STUDY OF AAV5-HRKP.RPGR FOR THE TREATMENT OF X-LINKED RETINITIS PIGMENTOSA ASSOCIATED WITH VARIANTS IN THE RPGR GENE

View on source registry